ABSTRACT
An animal model of otitis media using chinchillas was developed to evaluate the efficacy of tebipenem pivoxil (TBM-PI) against experimental otitis media. Chinchillas inoculated via the transbullar approach with Streptococcus pneumoniae serogroup 6 were included in the efficacy study with TBM-PI, amoxicillin (AMX) or untreated as controls. TBM-PI resulted in survival rate of 83%, compared with 25% survival for AMX and 0% survival for controls (p<0.01). Quantitative cultures in the middle ear effusions at day 5 of the TBM-PI group yielded 3.5+/-2.4log(10)CFUs/ml. TBM-PI is a promising antibiotic for the treatment of acute otitis media.
Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Otitis Media/drug therapy , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/isolation & purification , Administration, Oral , Amoxicillin/pharmacokinetics , Amoxicillin/pharmacology , Animals , Anti-Bacterial Agents/pharmacokinetics , Carbapenems/pharmacokinetics , Chinchilla , Male , Models, Animal , Otitis Media/metabolism , Otitis Media/microbiology , Penicillin Resistance , Pneumococcal Infections/metabolismABSTRACT
The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis.
